Site‐directed chemotherapy with a drug bound to anti‐idiotypic antibody to a lymphoma cell‐surface IgM

Esther Hurwitz*, Rina Kashi, Daphna Burowsky, Ruth Arnon, Joseph Haimovich

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Xenogeneic antibodies against the cell‐surface IgM of a B‐cell lymphoma (38C‐13) were coupled through a dextran bridge to the anti‐neoplastic drug, daunomycin. The conjugate maintained both its antibody and its drug activity. The effectiveness of the conjugate was tested in vivo in mice challenged with the 38C‐13 lymphoma. Drug conjugates of the idiotypic antibodies injected intraperitoneally 2 days after tumor transplantation almost completely inhibited tumor development. The controls, daunomycin‐dextran‐goat anti‐DNP, free daunomycin, or the antibodies alone had no effect or only delayed the tumor development.

Original languageEnglish
Pages (from-to)745-748
Number of pages4
JournalInternational Journal of Cancer
Volume31
Issue number6
DOIs
StatePublished - 15 Jun 1983

Fingerprint

Dive into the research topics of 'Site‐directed chemotherapy with a drug bound to anti‐idiotypic antibody to a lymphoma cell‐surface IgM'. Together they form a unique fingerprint.

Cite this